MAPT and Alzheimer disease: The new guidelines, better known as the NIA-AA research framework, could be used for observational and interventional research, which defines AD by three biomarkers in living person: β-amyloid (Aβ) deposition, including amyloid-PET, CSF Aβ42 or Aβ42/Aβ40 ratio; pathologic tau, including tau-PET, CSF phosphorylated tau (p-tau); Neurodegeneration, including fluorodeoxyglucose (FDG) PET, CSF total tau (t-tau) or brain structural MRI.